论文部分内容阅读
目的 :评价结核分枝杆菌MPT6 4和ESAT6DNA疫苗的保护效果。方法 :将BALB/C小鼠随机分为5组 ,分别用生理盐水 (A组 ) ,载体质粒 (B组 ) ,卡介苗 (C组 ) ,MPT6 4 (D组 ) ,ESAT6 (E组 )免疫小鼠 ,3周后以结核分枝杆菌H37Rv腹腔攻击小鼠。 5～ 10周后 ,观察肝、脾组织病理改变。结果 :结核分枝杆菌攻击 5周后 ,A、B组肝脏病变主要表现为中度充血 ,淋巴细胞聚集与上皮样细胞组成小结节 ,数量 1～ 2 /HPF。C ,D ,E组表现为轻 中度充血 ,淋巴细胞聚集与上皮样细胞组成中等大小结节 ,数量 3～ 7/HPF。攻击 10周后 ,A、B组肝脏病变主要表现为轻度充血 ,淋巴细胞聚集与上皮样细胞组成中等大小结节 ,数量 3～ 4 /HPF。C组轻度充血 ,淋巴细胞聚集与上皮样细胞组成中等大小结节 ,数量 7～ 9/HPF。D组为轻 中度充血 ,淋巴细胞聚集与上皮样细胞组成小结节 ,数量 4～ 5 /HPF。E组为轻度充血 ,淋巴细胞聚集与上皮样细胞组成中等大小结节 ,数量 4～ 8/HPF。攻击 10周后脾脏改变 :A组充血明显 ,脾小体增生 ,1例融合 ;B组未见明显变化 ;C组脾小体增生 ,融合显著 ;D组脾小体轻度增生融合 ;E组脾小体中度增生 ,融合。结论 :结核分枝杆菌MPT6 4和ESAT6DNA疫苗能增加机体抵抗力 ,并且起效较快 ,ESAT6DNA疫苗的保护效力比MPT6 4
Objective: To evaluate the protective effect of Mycobacterium tuberculosis MPT6 4 and ESAT6 DNA vaccine. Methods: BALB / C mice were randomly divided into five groups and immunized with saline (group A), carrier plasmid (group B), BCG (group C), MPT6 4 (group D) and ESAT6 Mice were challenged intraperitoneally with M. tuberculosis H37Rv after 3 weeks. After 5 to 10 weeks, observe the pathological changes of liver and spleen. Results: After 5 weeks of challenge with Mycobacterium tuberculosis, the pathological changes of liver in group A and group B mainly showed moderate hyperemia, lymphocyte aggregation and small nodules in epithelium - like cells, the number of which was 1 ~ 2 / HPF. C, D, E group showed mild to moderate congestion, lymphocyte aggregation and epithelial cells composed of medium-sized nodules, the number of 3 ~ 7 / HPF. After 10 weeks of attack, the liver lesions of group A and group B mainly showed mild hyperemia, lymphocyte aggregation and epithelial - like cells formed medium size nodules, the number of 3 ~ 4 / HPF. Group C mild hyperemia, lymphocyte aggregation and epithelial cells composed of medium size nodules, the number of 7 ~ 9 / HPF. D group was mild to moderate hyperemia, lymphocyte aggregation and epithelial-like cells composed of small nodules, the number of 4 ~ 5 / HPF. E group was mild hyperemia, lymphocyte aggregation and epithelial-like cells formed medium size nodules, the number of 4 ~ 8 / HPF. After 10 weeks of challenge, the spleen changes: the hyperemia in group A was obvious, splenic body hyperplasia and fusion in 1 case, but no obvious change in group B; the splenic body hyperplasia and fusion were obvious in group C; Spleen body moderate hyperplasia, fusion. Conclusion: Mycobacterium tuberculosis MPT6 4 and ESAT6 DNA vaccines can increase the body resistance and have a rapid onset of action. The protective efficacy of the ESAT6 DNA vaccine is higher than that of MPT6 4